Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA14508
Max Phase: Preclinical
Molecular Formula: C10H12ClFN2O2
Molecular Weight: 210.21
Molecule Type: Small molecule
Associated Items:
ID: ALA14508
Max Phase: Preclinical
Molecular Formula: C10H12ClFN2O2
Molecular Weight: 210.21
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: Cl.Oc1cc(F)c(CC2=NCCN2)cc1O
Standard InChI: InChI=1S/C10H11FN2O2.ClH/c11-7-5-9(15)8(14)3-6(7)4-10-12-1-2-13-10;/h3,5,14-15H,1-2,4H2,(H,12,13);1H
Standard InChI Key: SGPPHGCRDHZKQK-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 210.21 | Molecular Weight (Monoisotopic): 210.0805 | AlogP: 0.78 | #Rotatable Bonds: 2 |
Polar Surface Area: 64.85 | Molecular Species: BASE | HBA: 4 | HBD: 3 |
#RO5 Violations: 0 | HBA (Lipinski): 4 | HBD (Lipinski): 3 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: 8.41 | CX Basic pKa: 10.12 | CX LogP: 0.36 | CX LogD: -0.54 |
Aromatic Rings: 1 | Heavy Atoms: 15 | QED Weighted: 0.63 | Np Likeness Score: 0.03 |
1. Miller DD, Hamada A, Clark MT, Adejare A, Patil PN, Shams G, Romstedt KJ, Kim SU, Intrasuksri U, McKenzie JL.. (1990) Synthesis and alpha 2-adrenoceptor effects of substituted catecholimidazoline and catecholimidazole analogues in human platelets., 33 (4): [PMID:2157007] [10.1021/jm00166a009] |
Source(1):